Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. (Q50572228)

15 March 2018

title

Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. (English)

1 reference

15 March 2018

0 references

1 reference

4

1 reference

15 March 2018

author name string

Matthew P Muller

1

1 reference

15 March 2018

Linda Dresser

2

1 reference

15 March 2018

Janet Raboud

3

1 reference

15 March 2018

Elizabeth Rea

5

1 reference

15 March 2018

Susan E Richardson

6

1 reference

15 March 2018

Tony Mazzulli

7

1 reference

15 March 2018

Mark Loeb

8

1 reference

15 March 2018

Marie Louie

9

1 reference

15 March 2018

Canadian SARS Research Network

10

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 April 2007

1 reference

15 March 2018

published in

Pharmacotherapy

1 reference

15 March 2018

volume

27

1 reference

15 March 2018

issue

4

1 reference

15 March 2018

page(s)

494-503

1 reference

15 March 2018

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Lassa fever. Effective therapy with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Treatment of Bolivian hemorrhagic fever with intravenous ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Antiviral treatment of Argentine hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Hemorrhagic fever viruses as biological weapons: medical and public health management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

A major outbreak of severe acute respiratory syndrome in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Identification of severe acute respiratory syndrome in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Early diagnosis of SARS: lessons from the Toronto SARS outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

21 January 2018

SARS: pharmacotherapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

SARS: prognosis, outcome and sequelae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Severe acute respiratory syndrome: prognostic implications of chest radiographic findings in 52 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Multiple imputation: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Selection bias in observational and experimental studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Development of a standard treatment protocol for severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

Clinical characteristics, management and prognostic factors in patients with probable severe acute respiratory syndrome (SARS) in a SARS center in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.4.494

American Academy of Pediatrics Committee on Infectious Diseases: Use of ribavirin in the treatment of respiratory syncytial virus infection

21 January 2018

1 reference

12 December 2020

Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients

1 reference

12 December 2020

Hypocalcemia: a pervasive metabolic abnormality in the critically ill

1 reference

12 December 2020

Clinical course and management of SARS in health care workers in Toronto: a case series.

1 reference

12 December 2020

Multiple significance tests: the Bonferroni method

1 reference

12 December 2020

Severe Acute Respiratory Syndrome: Clinical Outcome and Prognostic Correlates

1 reference

12 December 2020

The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase

1 reference

12 December 2020

Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong

1 reference

12 December 2020

The multifactorial basis for hypocalcemia during sepsis. Studies of the parathyroid hormone-vitamin D axis.

1 reference

12 December 2020

Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.

1 reference

12 December 2020

Ribavirin in the treatment of SARS: A new trick for an old drug?

1 reference

12 December 2020

Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience.

1 reference

12 December 2020

Identifiers

DOI

10.1592/PHCO.27.4.494

1 reference

15 March 2018

1 reference

15 March 2018